• The DIALCAT project is a collaborative project of industrial research, experimental development and innovation in the Community RIS3CAT “TEC-SALUT”, managed by ACCIÓ and co-financed by the European Regional Development Fund (ERDF). The project is based on epidemiological data confirming that patients with diabetes have 2 to 3 times higher prevalence of severe cognitive impairment and […]

  • The MICROBIOTA project is a collaborative project of industrial research, experimental development and innovation in the Community RIS3CAT “INNOAPAT”, managed by ACCIÓ and co-financed by the European Regional Development Fund (ERDF).

  • Validating the effect of a drug or vaccine is crucial to know its real power. Anaxomics participated in the SysMalVac research project, integrating data from experimental assays and identifying biomarkers of immune protection to malaria.

  • Last 16-17 December, Anaxomics hosted in Barcelona the last meeting of the European research project CombiMS, aimed at fighting multiple sclerosis by finding new combination therapies and biomarkers, partly through the application of systems biology, the core competency of Anaxomics. In this meeting, the team discussed the progress that each partner has achieved, as well […]

  • Knowing personal skin-age related genetic polymorphisms is crucial to choose the best product for each costumer. Read our next post explaining how we created a line of genetically personalized cosmetics.

  • On September 17-18 2014, Anaxomics hosted the 24M-month meeting of the FP7 funded European project VISION at its headquarters in Barcelona, Spain. About thirty scientists from the five partner institutions and SMEs of the consortium participated in the meeting, which marked important milestones in the development of the project. Eduardo Soriano from CSIC, the scientific […]

  • The Anaxomics team published an article on the application of systems biology to the selection of nutraceutical treatments for NAFLD  in the NUTRAfoods  journal. This article describes the use of our proprietary TPMS technology to identify the best nutraceuticals for the treatment of NAFLD and to describe their action on the disease. You can read the […]

  • The transition from preclinical to clinical research marks a critical turning point in the drug development process. Unfortunately, despite high R&D expenditures, attrition rates remain high, with most drugs failing due to safety and efficacy issues. Discover the underlying causes of this long-standing problem and how systems biology can address it.

  • Are you involved in early drug development and need to compare the efficacy of your compound with other drug competitors? Do you want to test your hypotheses in human-physiology based models? Discover the Anaxomics customized in silico services for highlighting strengths of early-stage developmental compounds.

  • Anaxomics’s systems biology-based drug repositioning combines the best from the heuristic and rational drug repositioning approaches, while overcoming their limitations. We offer both companies and academic and clinic researchers this 75 % success rate technology, which has let us patent several drugs and drug combinations.

Recent from Blog and News

  • Dialcat-Imatge.png

    The DIALCAT project is a collaborative project of industrial research, experimental development and innovation in the Community RIS3CAT “TEC-SALUT”, managed by ACCIÓ and co-financed by the European Regional Development Fund (ERDF). The project is based on epidemiological data confirming that patients with diabetes have 2 to 3 times higher prevalence of severe cognitive impairment and […]
    Read more

    22nd Mar 2017
  • Microbiota-Imatge

    The MICROBIOTA project is a collaborative project of industrial research, experimental development and innovation in the Community RIS3CAT "INNOAPAT", managed by ACCIÓ and co-financed by the European Regional Development Fund (ERDF).
    Read more

    22nd Mar 2017
  • Transautophagy

    The professor and scientist Caty Casas Louzao, member of the group of research in Neuroplasticity and Regeneration of the Neurociences Institute at the UAB, will lead the action. COST is a European intergovernmental framework for Cooperation in Science and Technology. TRANSAUTOPHAGY aims to foster and extend multidisciplinary knowledge in autophagy to unravel details of its […]
    Read more

    17th Nov 2015
  • idibell

    Integral analysis of the patient’s will be possible through collaboration of IDIBELL researchers and Anaxomics. Systems biology is the computational and mathematical modelling of complex biological systems, which allows its analysis. It permits obtaining complex conclusions and new hypothesis from biological and biomedical research. It also enables the integration in a single analysis of all […]
    Read more

    06th Nov 2015
  • As we have previously explained, repurposing research aim is to discover if a drug, drug combination, active ingredient, nutritional product or other therapy approved for human use in one disease or condition can be used to create a medical solution in a different disease or condition. There are many examples of this drug repurposing in […]
    Read more

    18th May 2015

  • Follow us